by Biospring | Apr 26, 2022 | Data Science, Digital Health, Drug Development, Drug Discovery, Janssen, Najat Khan
We were delighted to host a discussion with Najat Khan, PhD, Chief Data Science Officer and Global Head of Strategy and Operations, Janssen Research & Development (R&D), Johnson and Johnson. As the Chief Data Science Officer, Dr. Khan leads a team of 100+ data...
by Biospring | Apr 26, 2022 | DNA, Drug Development, Drug Discovery, Life Sciences Technology, Proteins, Proteome, Proteomics
Proteomics is the study of proteins (the proteome) in a cell, tissue, or organism. This emerging sector of the life sciences is helping scientists gain a deeper understanding of molecular biology. Proteins are large, complex molecules present in all living organisms....
by Biospring | Apr 26, 2022 | Artificial Intelligence, Data, Drug Discovery, Health Care, John Baldoni, Pharma
We recently hosted a discussion with Dr. John Baldoni, one of Biospring’s Operational Experts. He is the Co-Founder and Chief Scientific Officer of SaponiQx, a recently formed vaccine discovery and development company. He’s also the CEO of the Atom...
by Biospring | Apr 25, 2022 | DNA, Drug Development, Drug Discovery, Manufacturing, Pharma, Supply Chain, Sybio, Synthetic Biology
Synthetic biology (synbio) is a life sciences technology that is transforming a broad range of industries including agriculture, chemicals, food, and medicine. Synbio applies engineering principles to biology and uses genomics to “code” organisms to yield a desired...
by Biospring | Apr 25, 2022 | Abzena, Biologics, Biotech, CDMO, COVID-19, Drug Development, Drug Discovery, Drug Manufacturing, Pharma, Sven Lee
We shared an overview on Abzena following our investment in July. Over the past few months, Abzena has launched a new facility in San Diego and has made several executive hires. We recently spoke with Sven Lee, Chief Business Officer at Abzena, and he provided us with...
